Auto-generated from public data. Not the firm's stated position.
Forty51 Ventures appears to focus on early-stage biotech companies developing therapeutics for niche disease areas, with recent portfolio activity suggesting a concentration in immunology and sleep-related conditions. Based on disclosed data, the firm typically deploys €1.5M to €3.0M per investment at pre-seed and seed stages, positioning itself as an early-stage capital provider for Swiss and European biotech founders.
Generated 15 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Auto-detected from Forty51 Ventures's website.
Co-founder of three multi-billion dollar biotech companies, raised over $1.75B in capital.
Ex-Head Investment Europe at Roivant, Principal Investments at Sofinnova, >10 years in R&D.
Ex-Head of Global Transactions at Roivant, Deputy Head M&A Roche, >40 closed transactions.
Physician-scientist with several approved medicines at Novartis, >30 preclinical projects.
Focus and check size from the firm's website. Website reachable as of Aug 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.